You have not created a stock watchlist. Create one now to track $ARDX!
Ardelyx Inc
Health Care
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic a… more
Conversation Volume
Last 60 days
There is not enough conversation volume about this stock
Key Opinion Leaders
Strongest 30-day focus on $ARDX by total mentions
Loading data...
Real-time Chart
Price Chart for $ARDX
Conviction History
Bullish vs Bearish Conviction over the last 30 days.
This color denotes Market Hours (US/Eastern)
There is not enough conversation volume about this stock
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
We've detected you're running a Microsoft browser so features may not work as expected. We strongly recommend you run Captain runs on the latest versions of Google Chrome, Firefox, or Safari.